HeimMLLCF • OTCMKTS
add
Molecular Partners AG
Við síðustu lokun
4,22 $
Árabil
4,00 $ - 10,14 $
Markaðsvirði
152,36 m. USD
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
SWX
Í fréttum
TipRanks
fyrir 14 klukkustundum
Molecular Partners Announces Workforce Reduction to Extend Cash Runway
2,71%
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (CHF) | mar. 2025info | Breyting á/á |
|---|---|---|
Tekjur | — | — |
Rekstrarkostnaður | 16,14 m. | 259,35% |
Nettótekjur | -16,77 m. | -48,09% |
Hagnaðarhlutfall | — | — |
Hagnaður á hvern hlut | -0,45 | — |
EBITDA | -15,59 m. | -2,21% |
Virkt skatthlutfall | 0,01% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (CHF) | mar. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 130,91 m. | -24,82% |
Heildareignir | 141,10 m. | -23,98% |
Heildarskuldir | 12,90 m. | -24,36% |
Eigið fé alls | 128,19 m. | — |
Útistandandi hlutabréf | 37,27 m. | — |
Eiginfjárgengi | 1,23 | — |
Arðsemi eigna | -26,94% | — |
Ávöxtun eigin fjár | -29,41% | — |
Peningaflæði
Breyting á handbæru fé
| (CHF) | mar. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | -16,77 m. | -48,09% |
Handbært fé frá rekstri | -17,08 m. | -0,18% |
Reiðufé frá fjárfestingum | 34,96 m. | 98,53% |
Reiðufé frá fjármögnun | -302,00 þ. | -0,67% |
Breyting á handbæru fé | 17,50 m. | 1.588,90% |
Frjálst peningaflæði | -13,72 m. | -22,38% |
Um
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Stofnsett
2004
Vefsvæði
Starfsfólk
159
